An ongoing clinical trial (SWOG 1929) where all patients with ES-SCLC receive induction frontline EP + atezolizumab but are consequently randomized to receive maintenance atezolizumab with or without talazoparib, is prospectively evaluating for SLFN11 positivity [54]. The gene discussed is SLFN11; the disease is small cell lung carcinoma.